These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7334139)

  • 1. Comparative bioavailability of propranolol: twice-daily versus four times-daily administration.
    Dvornik D; Kraml M; Dubuc J; Patterson-Kreuscher S; Milosovich G; Mullane JF
    J Clin Pharmacol; 1981; 21(11):472-6. PubMed ID: 7334139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relative bioavailability of a commercial propranolol hydrochloride tablet in man.
    Roscoe R; Cooper J; Wilson TW; Joshi NN; Midha KK
    Biopharm Drug Dispos; 1982; 3(2):105-14. PubMed ID: 7104460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of propranolol and bendrofluazide formulations.
    McAinsh J; Holmes BF; Baber NS; Young J
    Biopharm Drug Dispos; 1981; 2(2):167-75. PubMed ID: 7248480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials.
    Stoffel NU; Cercamondi CI; Brittenham G; Zeder C; Geurts-Moespot AJ; Swinkels DW; Moretti D; Zimmermann MB
    Lancet Haematol; 2017 Nov; 4(11):e524-e533. PubMed ID: 29032957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.
    Wagner JG
    Clin Pharmacol Ther; 1985 May; 37(5):481-7. PubMed ID: 3987171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of propranolol dosing schedules.
    Coelho JB; Dvornik D; Mullane JF; Kaufman J; Simon J; Krantz KD; Lee TY; Perdue HS; Weidler D
    Clin Pharmacol Ther; 1983 Oct; 34(4):440-7. PubMed ID: 6617065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ageing on the hepatic clearance of propranolol.
    Castleden CM; George CF
    Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presystemic and systemic glucuronidation of propranolol.
    Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
    Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls.
    Watson RG; Bastain W; Larkin KA; Hayes JR; McAinsh JA; Shanks RG
    Br J Clin Pharmacol; 1987 Oct; 24(4):527-35. PubMed ID: 3689632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propranolol absorption in untreated coeliac disease.
    Sandle GI; Ward A; Rawlins MD; Record CO
    Clin Sci (Lond); 1982 Jul; 63(1):81-5. PubMed ID: 7083769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative pharmacokinetic studies on the relative biologic availability of two propranolol preparations in patients with steady state essential hypertension].
    Rostock G; Faulhaber HD; Gohlke HR; Prehm C
    Pharmazie; 1986 Apr; 41(4):258-60. PubMed ID: 3725870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
    Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
    J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state pharmacokinetics of a novel extended-release metformin formulation.
    Timmins P; Donahue S; Meeker J; Marathe P
    Clin Pharmacokinet; 2005; 44(7):721-9. PubMed ID: 15966755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma propranolol concentration and dose in young, healthy volunteers.
    Dey M; Brisson J; Davis G; Enever R; Pray K; Zaim B; Dvornik D
    Biopharm Drug Dispos; 1986; 7(2):103-11. PubMed ID: 3708118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive efficacy of propranolol given twice daily.
    MacLeod SM; Hamet P; Kaplan H; Larochelle P; Nadeau J; Ogilvie RI; Rangno RE; Ruedy J; Sellers EM; Ti TY
    Can Med Assoc J; 1979 Sep; 121(6):737-40. PubMed ID: 391380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension.
    Serlin MJ; Orme ML; MacIver M; Green GJ; Sibeon RG; Breckenridge AM
    Br J Clin Pharmacol; 1983 May; 15(5):519-27. PubMed ID: 6860527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic interactions during multiple-dose administration of nisoldipine and propranolol.
    Shaw-Stiffel TA; Walker SE; Ogilvie RI; Leenen FH
    Clin Pharmacol Ther; 1994 Jun; 55(6):661-9. PubMed ID: 8004882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady state relative bioavailability and pharmacokinetics of oral propranolol in black and white North Americans.
    Sharoky M; Perkal M; Turner R; Lesko LJ
    Biopharm Drug Dispos; 1988; 9(5):447-56. PubMed ID: 3224162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of long acting propranolol. Implications for therapeutic use.
    Nace GS; Wood AJ
    Clin Pharmacokinet; 1987 Jul; 13(1):51-64. PubMed ID: 3304770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.